在药物诱导的肝损伤中,塞特拉林诱导的低血糖
Elio Mikhael1, Rita Slim1, Santa El Helou1
1Saint Joseph University of Beirut, Gastroenterology department, Beirut, Lebanon.
Hospital pharmacy
|September 25, 2024
概括
赛特拉林是一种选择性血清素再吸收抑制剂,在患有类固醇诱导的肝损伤的患者中有效治疗胆固醇性. 然而,它也引起了严重的低血糖症,这是非糖尿病人肝脏受损的罕见副作用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 胆固醇性肝损伤可能导致衰弱性炎.
- 选择性血清素再吸收抑制剂 (SSRI),如塞特拉林,用于非标签性管理.
- 滥用类固醇是一种已知的药物诱导性肝损伤的原因.
研究的目的:
- 报告一种罕见的塞特拉林诱导的低血糖症病例,该病例发生在患有类固醇诱导的肝损伤的患者身上.
- 突出使用塞特拉林在肝功能受损的患者中的潜在风险.
主要方法:
- 一名年轻男性患者的病例报告,患有类固醇诱导的肝损伤和.
- 使用塞特拉林 (SSRI) 的治疗.
- 监测肝功能测试和血糖水平.
主要成果:
- 塞特拉林的使用导致炎的缓解,肝功能测试的改善.
- 患者在开始服用塞特拉林后两天内出现严重的低血糖症.
- 低血糖是由于塞特拉林,这是一个罕见的副作用,特别是在非糖尿病患者肝损伤.
结论:
- 塞特拉林可以有效治疗肝损伤中的胆固醇性炎.
- 临床医生在处方塞特拉林时应警罕见的副作用,如低血糖症,特别是在肝功能障碍患者中.
- 需要进一步的研究,以了解肝损伤中塞特拉林诱导的低血糖症的机制.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
182
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
182
Oral Hypoglycemic Agents: Sulfonylureas
196
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
196
Hypoglycemia and Glucagon
207
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
207
Oral Hypoglycemic Agents: Glinides
145
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
145
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
103


